Twitter Facebook LinkedIn YouTube

Ventripoint Diagnostics (TSXV: VPT) shares Up 300% after receiving new license from Health Canada

Video Platform Video Management Video Solutions Video Player

Health Canada approved the company’s new VMS-PLUS™ machine and the 4-chamber heart analysis system. The company’s VMS machine was previously licensed in Canada to analyse the right ventricle, whereas this new license also includes the right atrium, left atrium and the left ventricle chambers of the heart.

Additional Information:

Company: Ventripoint Diagnostics
Website: http://www.ventripoint.com
Stock Symbol: TSXV: VPT
Date Published: Mar 2, 2017
Transcript: Available

Video Transcript:

I’m Isabelle Chatelaine for Investmentpitch Media

Ventripoint Diagnostics (TSXV:VPT) shares were up 300% today after receiving a new license from Health Canada.

Health Canada approved the company’s new VMS-PLUS™ machine and the 4-chamber heart analysis system.

The company’s VMS machine was previously licensed in Canada to analyse the right ventricle, whereas this new license also includes the right atrium, left atrium and the left ventricle chambers of the heart.

This expansion allows for the determination of volume and function for all four chambers of the heart using conventional 2D ultrasound, which until now, could only be provided by MRI.

Dr. George Adams, President and CEO, stated: “Ventripoint has achieved a ‘world first’ with the approval of a whole-heart analysis system for 2D ultrasound exams, which provides accurate and reliable measurements equivalent to MRI. I am excited to begin to market our 4C machine and generate value for our shareholders. With the license in Canada, Ventripoint now has ‘home-country approval’, which simplifies the registration process for VMS products in many countries. This is exactly what we've been striving for."

The size and function of all four chambers of the heart is increasingly recognized as critically important in monitoring patients' responses to cardiac medications and procedures and predicting outcomes

This information is often unavailable as access to cardiac MRI is very limited in many countries, including Canada.

However, 2D cardiac ultrasound is universally available and used in conjunction with the VMS-PLUS, ultrasound is capable of generating measurements equivalent to MRI.

This will enable patients to be fully evaluated using 2D ultrasound on each visit, in a few minutes, and allow for better monitoring of changes in the anatomy and function of the heart.

The company has been preparing submissions for other jurisdictions and will announce when they are submitted.

The shares are trading at $0.40, and with 32.1 million shares outstanding, the company is capitalized at $12.8 million.

For more information, please visit the company’s websites www.ventripoint.com, contact Dr. George Adams, President and CEO, at 519-803-6937 or email gadams@ventripoint.ca.

I’m Isabelle Chatelaine for Investmentpitch Media